Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
NurExone Biologic Inc. (NRXBF) had Normalized Pre-Tax Income of $-1.77M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-1.77M |
|
-- |
|
-- |
|
$1.76M |
|
$-1.76M |
|
$-0.01M |
|
$-1.77M |
|
|
Normalized Pre-Tax Income |
$-1.77M |
$-1.77M |
|
$-1.77M |
|
$-1.77M |
|
$-1.77M |
|
$-1.76M |
|
$-1.70M |
|
91.03M |
|
91.03M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$1.71M |
|
$0.72M |
|
$1.44M |
|
$3.15M |
|
$0.76M |
|
-- |
|
$0.38M |
|
$1.15M |
|
$2.00M |
|
$2.00M |
|
$2.00M |
|
92.05M |
|
| Cash Flow Statement Financials | |
$-1.24M |
|
$-0.00M |
|
$0.62M |
|
$2.14M |
|
$1.51M |
|
$-0.63M |
|
$0.43M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.24M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-88.21% |
|
-88.21% |
|
-56.12% |
|
-88.21% |
|
$0.02 |
|
$-0.01 |
|
$-0.01 |
|